• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agency of Health Technology Assessment of Uruguay
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canada’s Drug Agency (CDA-AMC)
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Healthcare Quality Institute
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Regione Emilia Romagna
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [24814 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2025     Basque Office for Health Technology Assessment (OSTEBA) [Intestinal ultrasound in inflammatory bowel disease: diagnostic effectiveness, cost-effectiveness and patient and health professional perspectives]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cognitive behavioural therapy: Evidence report for the S3 guideline on peri- and postmenopause - diagnostics and interventions]
2025     NIHR Health Services and Delivery Research programme Improving the experience of health services for trans and gender-diverse young people and their families: an exploratory qualitative study
2025     National Institute for Health and Care Excellence (NICE) Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment. NICE technology appraisal guidance 1063
2025     The Danish Health Technology Council (DHTC) [Analysis report on the management of persistent symptoms following meniscal injury]
2025     Basque Office for Health Technology Assessment (OSTEBA) [Cardiovascular monitoring systems using photoplethysmography]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [SSRI/SSNRI: Evidence report for the S3 guideline on peri- and postmenopause - diagnostics and interventions]
2025     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Proton therapy in cancer treatment: evaluation of safety, efficacy, effectiveness, and efficiency]
2025     National Institute for Health and Care Excellence (NICE) Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor. NICE technology appraisal guidance 1062
2025     The Danish Health Technology Council (DHTC) [Evaluation report concerning the SelfBack app for the treatment of non-specific low back pain]
2025     Basque Office for Health Technology Assessment (OSTEBA) [Intraoperative fluorescence imaging for cancer cell identification]
2025     National Institute for Health and Care Excellence (NICE) Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 1060
2025     The Danish Health Technology Council (DHTC) [Evaluation report concerning endovascular treatment of abdominal aortic aneurysms without rupture]
2025     Basque Office for Health Technology Assessment (OSTEBA) [Intrasaccular device for endovascular treatment of cerebral aneurysm]
2025     Agency for Care Effectiveness (ACE) Antibacterial envelope for implantable neurostimulator infection control
2025     National Institute for Health and Care Excellence (NICE) Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma. NICE technology appraisal guidance 1059
2025     The Danish Health Technology Council (DHTC) [Evaluation report concerning HAL-Guided transurethral resection of bladder tumors in adult patients with suspected non-muscle-invasive bladder cancer]
2025     Center for Outcomes Research and Economic Evaluation for Health (C2H) [Cost-effectiveness evaluation of the aortic stent graft (The GORE TAG Conformable Thoracic Stent Graft with ACTIVE CONTROL System) for thoracic aortic aneurysm and complicated type B aortic dissection]
2025     Agency for Care Effectiveness (ACE) Deep brain stimulators for treatment of Parkinson disease, dystonia or essential tremor
2025     National Institute for Health and Care Excellence (NICE) Omaveloxolone for treating Friedreich's ataxia in people 16 years and over (terminated appraisal). NICE technology appraisal guidance 1061
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Tumor biomarkers related to managing people with prostate cancer]
2025     Agency for Care Effectiveness (ACE) Elastomeric infusion pumps for outpatient parenteral antimicrobial therapy
2025     NIHR Health Technology Assessment programme Effects of pharmacological and non-pharmacological interventions for the management of sleep problems in people with fibromyalgia: a multi-methods evidence synthesis
2025     The Danish Health Technology Council (DHTC) [Evaluation report concerning supervised walking exercise for patients with intermittent claudication]
2025     NIHR Health Technology Assessment programme Stepping into day treatment approach versus inpatient treatment for adults with anorexia nervosa: the DAISIES RCT
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Algorithm for the management of low back pain with or without radicular pain]
2025     NIHR Health Technology Assessment programme Pramipexole in addition to mood stabilisers for treatment-resistant bipolar depression: the PAX-BD randomised double-blind placebo-controlled trial
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Next-generation medical devices: the rise of artificial intelligence]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Breast cancer treatment algorithm]
2025     National Institute for Health and Care Excellence (NICE) Leniolisib for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over. NICE highly specialised technologies guidance 33
2025     NIHR Health Technology Assessment programme Clinical and cost-effectiveness of detailed anomaly ultrasound screening in the first trimester: a mixed-methods study
2025     NIHR Health Services and Delivery Research programme Developing palliative and end-of-life care research partnerships in the North East and North Cumbria: a report on the first year of the RIPEN network
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Adaptive deep brain stimulation in Parkinson's disease]
2025     NIHR Health Services and Delivery Research programme Intersecting factors of disadvantage and discrimination and their effect on daily life during the coronavirus pandemic: the CICADA-ME mixed-methods study
2025     NIHR Health Services and Delivery Research programme The spiritual needs and care of children and young people with life-threatening or life-shortening conditions, and parents (SPARK): a mixed-method investigation
2025     NIHR Health Technology Assessment programme Risk assessment tools for predicting transfusion in surgery: a systematic review and meta-analysis
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Lung cancer treatment algorithm]
2025     National Institute for Health and Care Excellence (NICE) Olipudase alfa for treating acid sphingomyelinase deficiency (Niemann–Pick disease) type AB and type B. NICE highly specialised technologies guidance 32
2025     NIHR Health Technology Assessment programme Dismantling behavioural weight management interventions: component network meta-analysis of randomised controlled trials and real-world services
2025     NIHR Health Technology Assessment programme Behavioural weight management interventions for the treatment of obesity: network meta-analysis of trial and real-world individual participant data
2025     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Digital technology promoting health for children and adolescents - an evidence map]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Confirmed trichomonas vaginalis infection: pharmacological treatment]
2025     NIHR Health Technology Assessment programme Accuracy and clinical effectiveness of fetal growth monitoring strategies for the prediction of small for gestational age at birth: a systematic review and meta-analysis
2025     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Interventions to formal caregivers for increased patient safety]
2025     NIHR Health Services and Delivery Research programme Understanding and addressing factors affecting carers’ mental health during end-of-life caregiving: synopsis of meta synthesis of literature and stakeholder collaboration
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [A look at connected objects and their integration into remote monitoring]
2025     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Newborn screening for Metachromatic leukodystrophy (MLD)]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [International experiences in home hospitalization: challenges and possible solutions]
2025     NIHR Health Technology Assessment programme Developing evidence-based guidelines for describing potential benefits and harms within patient information leaflets/sheets (PILs) that inform and do not cause harm (PrinciPILs)
2025     NIHR Health Services and Delivery Research programme Proactive integrated consultation-liaison psychiatry for older medical inpatients: The HOME Study RCT of its effectiveness and cost-effectiveness
2025     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Accuracy of diagnostic algorithms for suspected or elevated risk of ovarian cancer]
2025     NIHR Health Services and Delivery Research programme Cancer in English prisons: a mixed-methods study of diagnosis, treatment, care costs and patient and staff experiences
2025     Center for Outcomes Research and Economic Evaluation for Health (C2H) Cost-effectiveness evaluation of tenapanor (Phozevel)
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Initiating a diagnostic and therapeutic measure in a person with signs and symptoms of pharyngitis/tonsillitis]
2025     NIHR Health Technology Assessment programme Compression Hosiery to Avoid the Post-Thrombotic Syndrome: a synopsis of the CHAPS RCT
2025     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Psychometric properties for instruments used to measure core outcomes for provoked vestibulodynia]
2025     Center for Outcomes Research and Economic Evaluation for Health (C2H) Cost-effectiveness evaluation of inclisiran (Leqvio)
2025     Health Information and Quality Authority (HIQA) Paediatric early warning systems in emergency settings: protocol for a systematic review of clinical guidelines
2025     NIHR Health Technology Assessment programme Optimal provision of opiate substitution therapy and needle and syringe programmes: a multi-method realist evaluation
2025     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Interventions for behavioural change in the aim of promoting health and preventing disability in the elderly]
2025     Center for Outcomes Research and Economic Evaluation for Health (C2H) Cost-effectiveness evaluation of semaglutide (Wegovy)
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tislelizumab (oesophageal squamous cell carcinoma, first line) – Benefit assessment according to §35a Social Code Book V]
2025     NIHR Health Technology Assessment programme Evaluating whole genome sequencing for rare diseases in newborn screening: evidence synthesis from a series of systematic reviews
2025     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Pharmacological treatment of polycystic ovary syndrome - health and quality of life in the short and long term]
2025     NIHR Health Services and Delivery Research programme After the disruptive innovation: How remote and digital services were embedded, blended and abandoned in UK general practice – longitudinal study
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Glofitamab (DLBCL, combination with gemcitabine and oxaliplatin) – Benefit assessment according to §35a Social Code Book V]
2025     NIHR Health Services and Delivery Research programme Health visiting in the UK in light of the COVID-19 pandemic experience (RReHOPE): study synopsis
2025     Center for Outcomes Research and Economic Evaluation for Health (C2H) [Cost-effectiveness evaluation of Ritlecitinib tosylate (Litfulo)]
2025     NIHR Health Services and Delivery Research programme Barriers to and outcomes of unspecified kidney donation in the UK: BOUnD, a mixed-methods study
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Glofitamab (DLBCL, monotherapy, third line or later) – Benefit assessment according to §35a Social Code Book V]
2025     Haute Autorite de sante (HAS) [Second-line non-invasive skin imaging techniques, including in vivo reflectance confocal microscopy (RCM), for the diagnosis and preoperative mapping of melanoma]
2025     NIHR Health Services and Delivery Research programme Enhancing referrals to child and adolescent mental health services: the EN-CAMHS mixed-methods study
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Upadacitinib (giant cell arteritis) – Benefit assessment according to §35a Social Code Book V]
2025     NIHR Health Technology Assessment programme Interventions that challenge established and accepted clinical practice: lessons learnt from a process evaluation of the STOP-APE trial
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Letermovir (CMV prophylaxis after stem cell transplantation, < 18 years) – Benefit assessment according to §35a Social Code Book V]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Principles and criteria to guide the use of whole-genome sequencing versus targeted gene sequencing for the detection of somatic variants in oncology]
2025     Agency for Care Effectiveness (ACE) Mavacamten for treating obstructive hypertrophic cardiomyopathy
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Letermovir (CMV prophylaxis after stem cell transplantation, < 18 years) – Benefit assessment according to §35a Social Code Book V]
2025     NIHR Health Technology Assessment programme Learnings from the establishment and delivery of the UK Collaborative Paediatric Palliative Care Research Network
2025     Agency for Care Effectiveness (ACE) Finerenone for treating chronic kidney disease and albuminuria associated with type 2 diabetes
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Garadacimab (hereditary angioedema) – Addendum to Project A25-41]
2025     Swiss Federal Office of Public Health (FOPH) Magnesium supplements for muscle cramps and for the prevention of recurrent urinary tract stones
2025     NIHR Health Technology Assessment programme Establishing palliative care research partnerships in Northern Ireland
2025     Agency for Care Effectiveness (ACE) Epcoritamab for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [IQWiG benefit assessments based on systematic reviews: A comparative overview]
2025     Swiss Federal Office of Public Health (FOPH) Point-of-care diagnostic tests
2025     NIHR Health Services and Delivery Research programme Clinical and cost-effectiveness of paramedics working in general practice: a mixed-methods realist evaluation
2025     Agency for Care Effectiveness (ACE) Atogepant and rimegepant for prophylaxis of migraine
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Perinatal pathway: supporting women in a handicap situation related to a physical disability, an intellectual disability or autism]
2025     Basque Office for Health Technology Assessment (OSTEBA) [Effectiveness and safety of adaptive radiation therapy in patients with lymphoma, head and neck cancer or lung carcinoma]
2025     Swiss Federal Office of Public Health (FOPH) Multigene-expression tests for breast cancer
2025     NIHR Health Services and Delivery Research programme Optimisation of the deployment of automated external defibrillators in public places in England
2025     Agency for Care Effectiveness (ACE) Asciminib for Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase after two or more tyrosine kinase inhibitors
2025     NIHR Health and Social Care Delivery Program Optimising the delivery and impacts of interventions to improve hospital doctors’ workplace wellbeing in the NHS: The Care Under Pressure 3 realist evaluation study
2025     Basque Office for Health Technology Assessment (OSTEBA) [Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of children with peritoneal carcinomatosis]
2025     NIHR Health Technology Assessment programme Understanding the effectiveness and underlying mechanisms of lifestyle modification interventions in adults with learning disabilities: a mixed-methods systematic review
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Food allergen-specific IgG4 (immunoglobulin G4) measurement by immunoassay]
2025     National Institute for Health and Care Excellence (NICE) Guselkumab for treating moderately to severely active ulcerative colitis. NICE technology appraisal guidance 1094
2025     Basque Office for Health Technology Assessment (OSTEBA) [Efficacy and safety of non-invasive brain stimulation therapies for the neurorehabilitation of patients with stroke]
2025     National Institute for Health and Care Excellence (NICE) Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection. NICE technology appraisal guidance 1043